Literature DB >> 26921946

Probing Biased Signaling in Chemokine Receptors.

Roxana-Maria Amarandi1, Gertrud Malene Hjortø2, Mette Marie Rosenkilde2, Stefanie Karlshøj3.   

Abstract

The chemokine system mediates leukocyte migration during homeostatic and inflammatory processes. Traditionally, it is described as redundant and promiscuous, with a single chemokine ligand binding to different receptors and a single receptor having several ligands. Signaling of chemokine receptors occurs via two major routes, G protein- and β-arrestin-dependent, which can be preferentially modulated depending on the ligands or receptors involved, as well as the cell types or tissues in which the signaling event occurs. The preferential activation of a certain signaling pathway to the detriment of others has been termed signaling bias and can accordingly be grouped into ligand bias, receptor bias, and tissue bias. Bias has so far been broadly overlooked in the process of drug development. The low number of currently approved drugs targeting the chemokine system, as well as the broad range of failed clinical trials, reflects the need for a better understanding of the chemokine system. Thus, understanding the character, direction, and consequence of biased signaling in the chemokine system may aid the development of new therapeutics. This review describes experiments to assess G protein-dependent and -independent signaling in order to quantify chemokine system bias.
© 2016 Elsevier Inc. All rights reserved.

Keywords:  7TMR; Bias; Chemokine system; Chemotaxis; ERK; GPCR; GTPγS; IP(3); Internalization; cAMP; β-Arrestin

Mesh:

Substances:

Year:  2015        PMID: 26921946     DOI: 10.1016/bs.mie.2015.09.001

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  9 in total

1.  Molecular Mechanism of Action for Allosteric Modulators and Agonists in CC-chemokine Receptor 5 (CCR5).

Authors:  Stefanie Karlshøj; Roxana Maria Amarandi; Olav Larsen; Viktorija Daugvilaite; Anne Steen; Matjaž Brvar; Aurel Pui; Thomas Michael Frimurer; Trond Ulven; Mette Marie Rosenkilde
Journal:  J Biol Chem       Date:  2016-11-10       Impact factor: 5.157

Review 2.  Biased GPCR signaling: Possible mechanisms and inherent limitations.

Authors:  Vsevolod V Gurevich; Eugenia V Gurevich
Journal:  Pharmacol Ther       Date:  2020-03-19       Impact factor: 12.310

Review 3.  Allosteric Modulation of Class A GPCRs: Targets, Agents, and Emerging Concepts.

Authors:  Eric A Wold; Jianping Chen; Kathryn A Cunningham; Jia Zhou
Journal:  J Med Chem       Date:  2018-08-28       Impact factor: 7.446

Review 4.  Co-receptor signaling in the pathogenesis of neuroHIV.

Authors:  E A Nickoloff-Bybel; L Festa; O Meucci; P J Gaskill
Journal:  Retrovirology       Date:  2021-08-24       Impact factor: 4.602

5.  Differential CCR7 Targeting in Dendritic Cells by Three Naturally Occurring CC-Chemokines.

Authors:  Gertrud M Hjortø; Olav Larsen; Anne Steen; Viktorija Daugvilaite; Christian Berg; Suzan Fares; Morten Hansen; Simi Ali; Mette M Rosenkilde
Journal:  Front Immunol       Date:  2016-12-09       Impact factor: 7.561

6.  CCR7 Sulfotyrosine Enhances CCL21 Binding.

Authors:  Andrew J Phillips; Deni Taleski; Chad A Koplinski; Anthony E Getschman; Natasha A Moussouras; Amanda M Richard; Francis C Peterson; Michael B Dwinell; Brian F Volkman; Richard J Payne; Christopher T Veldkamp
Journal:  Int J Mol Sci       Date:  2017-08-25       Impact factor: 5.923

Review 7.  The Role of PDE8 in T Cell Recruitment and Function in Inflammation.

Authors:  Paul M Epstein; Chaitali Basole; Stefan Brocke
Journal:  Front Cell Dev Biol       Date:  2021-04-16

Review 8.  Chemokine Receptor-Targeted Therapies: Special Case for CCR8.

Authors:  Bernhard Moser
Journal:  Cancers (Basel)       Date:  2022-01-20       Impact factor: 6.639

Review 9.  Latest update on chemokine receptors as therapeutic targets.

Authors:  Wing Yee Lai; Anja Mueller
Journal:  Biochem Soc Trans       Date:  2021-06-30       Impact factor: 5.407

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.